Abstract
Eighteen patients with advanced cancer have been treated intravenously with human recombinant tumour necrosis factor (rhTNF). The drug produced febrile reactions at all doses although these were preventable by steroids and indomethacin. Doses at or above 9 x 10(5) units (400 micrograms)m-2 were associated with hypotension, abnormal liver enzymes, leucopenia and mild renal impairment in a substantial proportion of patients. RhTNF was cleared from plasma with a half life of approximately 20 minutes but non-linear pharmacokinetics lymphoma, improvements in their tumours were recorded. RhTNF was noted to produce rapid increases in serum C-reactive protein concentrations. Endogenous TNF levels were not found to be elevated in 72 cancer patients. TNF deserves further therapeutic evaluation and these observations support its biological importance as an endogenous pyrogen, mediator of acute phase protein responses, and a mediator of endotoxic shock.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Selby, P., Hobbs, S., Viner, C. et al. Tumour necrosis factor in man: Clinical and biological observations. Br J Cancer 56, 803–808 (1987). https://doi.org/10.1038/bjc.1987.294
Issue Date:
DOI: https://doi.org/10.1038/bjc.1987.294
This article is cited by
-
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
npj Precision Oncology (2023)
-
The role of Tumor necrosis factor alpha −308 G>A promoter polymorphism in pediatric community acquired pneumonia
Egyptian Pediatric Association Gazette (2020)
-
The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches
Cellular Oncology (2020)
-
IL-33 Treatment Attenuates the Systemic Inflammation Reaction in Acinetobacter baumannii Pneumonia by Suppressing TLR4/NF-κB Signaling
Inflammation (2018)
-
The effect of resistance training on markers of immune function and inflammation in previously sedentary women recovering from breast cancer: a randomized controlled trial
Breast Cancer Research and Treatment (2016)